scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
23 hedge funds and large institutions have $94.4M invested in scPharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.22% more ownership
Funds ownership: 0% → 44.22% (+44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$48.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$40.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.82M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.54M |
Top Sellers
SCPH Hedge Fund Activity: Q4 2017 in Review
23 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2017, worth a combined $94.4M.
Buyers outnumbered sellers: 23 funds opened new SCPH positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $48.1M.
- 23 institutional investors held scPharmaceuticals (SCPH) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $94.4M of scPharmaceuticals stock for Q4 2017.
- 23 funds opened new scPharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +23 holders.
- The largest scPharmaceuticals buyer in Q4 2017 was OrbiMed, an estimated $48.1M added.
Based on aggregated 13F filings for Q4 2017.